Antiplatelet and anticoagulant therapy in elderly people with type 2 diabetes mellitus in Poland (based on the PolSenior Study)
Introduction: Type 2 diabetes mellitus (T2DM) is an important and common cardiovascular risk factor. The purpose of the study was to evaluate the frequency of use of oral antiplatelet drugs (OAPs) and oral anticoagulant drugs (OACs) among the elderly with T2DM in Poland. Material and methods:...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Termedia Publishing House
2017-07-01
|
| Series: | Archives of Medical Science |
| Subjects: | |
| Online Access: | https://www.termedia.pl/Antiplatelet-and-anticoagulant-therapy-in-elderly-people-with-type-2-diabetes-mellitus-in-Poland-based-on-the-PolSenior-Study-,19,30311,1,1.html |
| _version_ | 1819055321130205184 |
|---|---|
| author | Beata Łabuz-Roszak Agnieszka Machowska-Majchrzak Michał Skrzypek Małgorzata Mossakowska Jerzy Chudek Andrzej Więcek Maciej Wawrzyńczyk Beata Łącka-Gaździk Krystyna Pierzchała |
| author_facet | Beata Łabuz-Roszak Agnieszka Machowska-Majchrzak Michał Skrzypek Małgorzata Mossakowska Jerzy Chudek Andrzej Więcek Maciej Wawrzyńczyk Beata Łącka-Gaździk Krystyna Pierzchała |
| author_sort | Beata Łabuz-Roszak |
| collection | DOAJ |
| description | Introduction: Type 2 diabetes mellitus (T2DM) is an important and common cardiovascular risk factor. The purpose of the study was to evaluate the frequency of use of oral antiplatelet drugs (OAPs) and oral anticoagulant drugs (OACs) among the elderly with T2DM in Poland.
Material and methods: The study was based on the data collected in the Polish national PolSenior study.
Results: Among 4979 PolSenior participants aged 65 and over, 883 (17.8%) had previously diagnosed T2DM. Among them, 441 (49.9%) used at least one drug in pharmacological cardiovascular prevention, i.e. OAPs (mostly ASA) in 405 (45.9%) cases and OACs in 38 (4.3%). The use of these drugs significantly depended on the sex (p = 0.02) and personal income (p = 0.05). Age, place of residence and level of education did not affect the prevalence of pharmacological prevention. Previous stroke and myocardial infarction were mostly associated with OAPs, whereas a history of atrial fibrillation (AF) was related to OAC treatment. Among participants treated with OAPs, therapy was applied as secondary cardiovascular prevention in 211 (52.1%) subjects, and as primary prevention in 194 (47.9%) subjects. Among participants treated with OACs, 24 (64.9%) persons had a history of AF. Secondary cardiovascular pharmacological prevention should be considered in 45 untreated participants (12.5%), and primary cardiovascular pharmacological prevention (SCORE ≥ 10 and/or AF) in 154 participants (42.7%).
Conclusions : Cardiovascular pharmacological prevention in the elderly with T2DM in Poland seems to be unsatisfactory. Educational programmes concerning current recommendations for pharmacological cardiovascular prevention should be developed among general practitioners. |
| first_indexed | 2024-12-21T13:05:39Z |
| format | Article |
| id | doaj.art-27c4ca57a7be44f188e5670ddde7bc63 |
| institution | Directory Open Access Journal |
| issn | 1734-1922 1896-9151 |
| language | English |
| last_indexed | 2024-12-21T13:05:39Z |
| publishDate | 2017-07-01 |
| publisher | Termedia Publishing House |
| record_format | Article |
| series | Archives of Medical Science |
| spelling | doaj.art-27c4ca57a7be44f188e5670ddde7bc632022-12-21T19:03:02ZengTermedia Publishing HouseArchives of Medical Science1734-19221896-91512017-07-011351018102410.5114/aoms.2017.6894830311Antiplatelet and anticoagulant therapy in elderly people with type 2 diabetes mellitus in Poland (based on the PolSenior Study)Beata Łabuz-RoszakAgnieszka Machowska-MajchrzakMichał SkrzypekMałgorzata MossakowskaJerzy ChudekAndrzej WięcekMaciej WawrzyńczykBeata Łącka-GaździkKrystyna PierzchałaIntroduction: Type 2 diabetes mellitus (T2DM) is an important and common cardiovascular risk factor. The purpose of the study was to evaluate the frequency of use of oral antiplatelet drugs (OAPs) and oral anticoagulant drugs (OACs) among the elderly with T2DM in Poland. Material and methods: The study was based on the data collected in the Polish national PolSenior study. Results: Among 4979 PolSenior participants aged 65 and over, 883 (17.8%) had previously diagnosed T2DM. Among them, 441 (49.9%) used at least one drug in pharmacological cardiovascular prevention, i.e. OAPs (mostly ASA) in 405 (45.9%) cases and OACs in 38 (4.3%). The use of these drugs significantly depended on the sex (p = 0.02) and personal income (p = 0.05). Age, place of residence and level of education did not affect the prevalence of pharmacological prevention. Previous stroke and myocardial infarction were mostly associated with OAPs, whereas a history of atrial fibrillation (AF) was related to OAC treatment. Among participants treated with OAPs, therapy was applied as secondary cardiovascular prevention in 211 (52.1%) subjects, and as primary prevention in 194 (47.9%) subjects. Among participants treated with OACs, 24 (64.9%) persons had a history of AF. Secondary cardiovascular pharmacological prevention should be considered in 45 untreated participants (12.5%), and primary cardiovascular pharmacological prevention (SCORE ≥ 10 and/or AF) in 154 participants (42.7%). Conclusions : Cardiovascular pharmacological prevention in the elderly with T2DM in Poland seems to be unsatisfactory. Educational programmes concerning current recommendations for pharmacological cardiovascular prevention should be developed among general practitioners.https://www.termedia.pl/Antiplatelet-and-anticoagulant-therapy-in-elderly-people-with-type-2-diabetes-mellitus-in-Poland-based-on-the-PolSenior-Study-,19,30311,1,1.htmldiabetes mellitus elderly anticoagulant drugs antiplatelet drugs |
| spellingShingle | Beata Łabuz-Roszak Agnieszka Machowska-Majchrzak Michał Skrzypek Małgorzata Mossakowska Jerzy Chudek Andrzej Więcek Maciej Wawrzyńczyk Beata Łącka-Gaździk Krystyna Pierzchała Antiplatelet and anticoagulant therapy in elderly people with type 2 diabetes mellitus in Poland (based on the PolSenior Study) Archives of Medical Science diabetes mellitus elderly anticoagulant drugs antiplatelet drugs |
| title | Antiplatelet and anticoagulant therapy in elderly people with type 2 diabetes mellitus in Poland (based on the PolSenior Study) |
| title_full | Antiplatelet and anticoagulant therapy in elderly people with type 2 diabetes mellitus in Poland (based on the PolSenior Study) |
| title_fullStr | Antiplatelet and anticoagulant therapy in elderly people with type 2 diabetes mellitus in Poland (based on the PolSenior Study) |
| title_full_unstemmed | Antiplatelet and anticoagulant therapy in elderly people with type 2 diabetes mellitus in Poland (based on the PolSenior Study) |
| title_short | Antiplatelet and anticoagulant therapy in elderly people with type 2 diabetes mellitus in Poland (based on the PolSenior Study) |
| title_sort | antiplatelet and anticoagulant therapy in elderly people with type 2 diabetes mellitus in poland based on the polsenior study |
| topic | diabetes mellitus elderly anticoagulant drugs antiplatelet drugs |
| url | https://www.termedia.pl/Antiplatelet-and-anticoagulant-therapy-in-elderly-people-with-type-2-diabetes-mellitus-in-Poland-based-on-the-PolSenior-Study-,19,30311,1,1.html |
| work_keys_str_mv | AT beatałabuzroszak antiplateletandanticoagulanttherapyinelderlypeoplewithtype2diabetesmellitusinpolandbasedonthepolseniorstudy AT agnieszkamachowskamajchrzak antiplateletandanticoagulanttherapyinelderlypeoplewithtype2diabetesmellitusinpolandbasedonthepolseniorstudy AT michałskrzypek antiplateletandanticoagulanttherapyinelderlypeoplewithtype2diabetesmellitusinpolandbasedonthepolseniorstudy AT małgorzatamossakowska antiplateletandanticoagulanttherapyinelderlypeoplewithtype2diabetesmellitusinpolandbasedonthepolseniorstudy AT jerzychudek antiplateletandanticoagulanttherapyinelderlypeoplewithtype2diabetesmellitusinpolandbasedonthepolseniorstudy AT andrzejwiecek antiplateletandanticoagulanttherapyinelderlypeoplewithtype2diabetesmellitusinpolandbasedonthepolseniorstudy AT maciejwawrzynczyk antiplateletandanticoagulanttherapyinelderlypeoplewithtype2diabetesmellitusinpolandbasedonthepolseniorstudy AT beatałackagazdzik antiplateletandanticoagulanttherapyinelderlypeoplewithtype2diabetesmellitusinpolandbasedonthepolseniorstudy AT krystynapierzchała antiplateletandanticoagulanttherapyinelderlypeoplewithtype2diabetesmellitusinpolandbasedonthepolseniorstudy |